These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37819945)

  • 1. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.
    Pifer PM; Yang L; Kumar M; Xie T; Frederick M; Hefner A; Beadle B; Molkentine D; Molkentine J; Dhawan A; Abdelhakiem M; Osman AA; Leibowitz BJ; Myers JN; Pickering CR; Sandulache VC; Heymach J; Skinner HD
    Clin Cancer Res; 2024 Jan; 30(1):187-197. PubMed ID: 37819945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
    Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.
    Skinner HD; Giri U; Yang L; Woo SH; Story MD; Pickering CR; Byers LA; Williams MD; El-Naggar A; Wang J; Diao L; Shen L; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
    Clin Cancer Res; 2016 Sep; 22(18):4643-50. PubMed ID: 27036135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
    Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
    Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
    Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 mutations in head and neck cancer.
    Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
    Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.
    Zhang J; Chen T; Yang X; Cheng H; Späth SS; Clavijo PE; Chen J; Silvin C; Issaeva N; Su X; Yarbrough WG; Annunziata CM; Chen Z; Van Waes C
    Cancer Res; 2018 Aug; 78(16):4613-4626. PubMed ID: 29921694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
    Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
    Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Shaikh MH; Dawson A; Prokopec SD; Barrett JW; Y F Zeng P; Khan MI; Ryan SEB; Cecchini M; Palma DA; Mymryk JS; Boutros PC; Nichols AC
    Oral Oncol; 2023 Nov; 146():106580. PubMed ID: 37778229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.